Table 4.
Comparison with other studies
| Institute | Year | No. | disease | treatment | TD, GyE | Follow-up, months | LC | OS |
|---|---|---|---|---|---|---|---|---|
| HIT 28 | 2015 | 56 | chordoma | C or C+PH | 66 (60-74) | 25 (range: NA) | 2y: 76% 3 y: 53% |
2 y: 100% 3 y: 100% |
| NIRS 9 | 2017 | 73 | ChSa | C | 70.4 (64-73.6) | 49.4 (6.4-146.4) | 5 y: 53% | 5 y: 53% |
| NIRS 29 | 2016 | 188 | Chordoma | C | 67.2 (64-73.6) | 62 (6.8-147.5) | 1 y: 99% 5 y: 77% |
1 y: NA 5 y: 81% |
| HIBMC 7 | 2014 | 23 | chordoma | C or P | 70.4 | 38 (7-78) | 3 y: 94% | 3 y: 83% |
| MGH 30 | 2015 | 126 | chordoma | P | 72.4 (46.3-83.6) | 41 (range: NA) | 5 y: 62% | 5 y: 81% |
| MC 31 | 2005 | 52 | chordoma | Surgery | NA | 93.6 (25.2-276) | 5 y: 59% | 5 y: 74% |
| IOR/INT 32 | 2010 | 130 | Chordoma | Surgery | NA | 142 (76-210) | 5 y: 52% | 5 y: 78% |
| Present | 2018 | 21 | ChSa /chordoma | C | 69 (57-80) | 21.8 (7.2-39.2) | 1 y: 93.8% 2 y: 85.2% |
1 y: 100% 2 y: 100% |
ChSa: chondrosarcoma; C: carbon ion radiotherapy; P: proton radiotherapy; PH: photon radiotherapy; TD: total dose; GyE: gray equivalents; LC: local control; OS: overall survival; HIT: Heidelberg Ion Beam Therapy Center; NIRS: National Institute of Radiological Sciences; HIBMC: Hyogo Ion Beam Medical Center; MGH: Massachusetts General Hospital; MC: Mayo Clinic; IOR: Istituto Ortopedico Rizzoli; INT: Istituto Nazionale Tumori.